Windtree Goes Crypto: Nasdaq Giant Bets Big with $60M BNB Purchase

Wall Street meets Web3—and this time, it's not just talk.

Big Pharma's Crypto Pivot

Windtree Therapeutics, the Nasdaq-listed biotech player, just dropped a bombshell: a $60 million dive into Binance's BNB token. Because nothing says 'innovation' like a pharma company moonlighting as a crypto hedge fund.

Timing Is Everything

The move comes as institutional crypto FOMO hits fever pitch. Forget drug pipelines—Windtree's new growth strategy involves HODLing and praying the SEC doesn't blink.

The Bottom Line

Another day, another corporate treasury gambling with shareholder money on volatile digital assets. At least they didn't buy Dogecoin.

More “micro strategies”

The initiative comes as corporate participants across the crypto market up their game with key balance sheet strategy moves.

While Bitcoin (BTC) has seen the most robust buying by publicly-listed companies, altcoins are attracting significant attention. Ethereum, Ripple’s XRP and Solana have all seen massive investment plans, with many inspired by Michael Saylor’s Strategy.

BNB is also becoming a key target for public companies as the Binance ecosystem strengthens its position as the world’s leading crypto exchange.

Changpeng Zhao, founder of Binance and former chief executive officer, notes that Windtree is one more “micro strategy” for BNB. He commented via X:

More BNB "micro strategies"… 👏 https://t.co/EvADNdm6Ii

The BNB token ranks as a top 10 cryptocurrency by market cap and records an average of $2 billion in daily trading volume.

“This transaction secures up to $200 million from institutional investors, offering our shareholders a unique opportunity to gain exposure to a BNB-focused crypto treasury strategy,” said Jed Latkin, chief executive officer of Windtree.

Windtree’s plans for a BNB treasury strategy comes just days after YZi Labs, formerly Binance Labs, backed a new BNB-focused treasury firm.

Nano Labs, another Nasdaq-listed company, is also buying BNB.